- Home
- BSM vs HCM Comparison
BSM vs HCM Comparison
Compare BSM & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- HCM
- Stock Information
- Founded
- BSM 1876
- HCM 2000
- Country
- BSM United States
- HCM Hong Kong
- Employees
- BSM N/A
- HCM N/A
- Industry
- BSM Oil & Gas Production
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- HCM Health Care
- Exchange
- BSM Nasdaq
- HCM Nasdaq
- Market Cap
- BSM 2.5B
- HCM 2.6B
- IPO Year
- BSM 2015
- HCM N/A
- Fundamental
- Price
- BSM $12.79
- HCM $17.64
- Analyst Decision
- BSM Hold
- HCM
- Analyst Count
- BSM 1
- HCM 0
- Target Price
- BSM $13.00
- HCM N/A
- AVG Volume (30 Days)
- BSM 518.4K
- HCM 57.4K
- Earning Date
- BSM 11-03-2025
- HCM 08-07-2025
- Dividend Yield
- BSM 9.38%
- HCM N/A
- EPS Growth
- BSM N/A
- HCM N/A
- EPS
- BSM 1.16
- HCM 0.53
- Revenue
- BSM $413,675,000.00
- HCM $602,197,000.00
- Revenue This Year
- BSM $10.58
- HCM $2.73
- Revenue Next Year
- BSM $14.68
- HCM $17.33
- P/E Ratio
- BSM $11.00
- HCM $6.26
- Revenue Growth
- BSM N/A
- HCM N/A
- 52 Week Low
- BSM $11.78
- HCM $11.51
- 52 Week High
- BSM $15.66
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- BSM 54.37
- HCM 61.77
- Support Level
- BSM $11.78
- HCM $17.19
- Resistance Level
- BSM $12.63
- HCM $18.30
- Average True Range (ATR)
- BSM 0.17
- HCM 0.34
- MACD
- BSM -0.59
- HCM 0.29
- Stochastic Oscillator
- BSM 99.77
- HCM 81.58
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.